Currently resident in JLabs New York City, Aggamin is a bio-medical company structured around addressing the unmet medical needs of women with the lead effort being is focused on preeclampsia a currently untreatable disease affecting a significant percentage of pregnancies with a high annual cost to US health care system. The firm's drug therapy works to restore the angiogenic balance that is disrupted in preeclampsia. The effect is to reverse maternal symptoms and to prolong pregnancy toward 36 weeks of gestation - an improvement that can enable safe and full term delivery. Issued IP for validated pathways, the firm have successfully commercialized diagnostic for indication creating market for therapy.
